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ABSTRACT
Approximately 92,000 ureteral stents are implanted every year to maintain urine
flow after treatment of kidney stones, kidney transplants, and urinary incontinence.
However, current ureteral stents have several downsides that include encrustation,
urgency due to the proximal curl pressing on the bladder, patient pain from inflexible
stents, and most importantly, the need for a follow up removal surgery. To address many
of these current issues, a novel biodegradable stent was designed, fabricated, and
characterized in the present studies. The innovative stent design features the use of
biodegradable, FDA approved polydioxanone polymer material that was aimed to reduce
encrustation and eliminate the need for a removal surgery. Additionally, the stent’s novel
coiled shape is intended to provide flexibility and anchor into the ureter. By eliminating
the clinically conventional “double J” anchors, this could prevent the issue of the
proximal anchor pressing on the bladder, remove the risk of encrustation on the distal
anchor, and provide for better patient comfort by creating a more axially flexible stent.
The novel stent was fabricated by winding a PDO suture around a mandrel and annealing
at 100 °C. This annealing step increased the stiffness of the polymer as determined by
cantilever bend testing. The source of this stiffness increase was determined to be due to
an increase in crystallinity as verified by Differential Scanning Calorimetry and Wide
Angle X-Ray Scattering. The results of custom testing in the present study also provided
evidence that the stent exhibits adequate anchor strength and radial strength to maintain
patency, which would allow standard ureteral flow conditions. Finally, an in vitro
experiment demonstrated that the stent degrades in four weeks under normal
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physiological conditions, which is believed to be the ideal degradation time for the
majority of ureteral stent applications. The results of this thesis provide strong
supporting evidence that the proposed stent design has the ability to improve patient
outcomes by addressing the drawbacks of current stent technology. However, further
characterization efforts using animal models will be necessary to assure the safety and
efficacy of this technology before it is ready for clinical use.
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1. LITERATURE REVIEW

1.1 Clinical Motivation
To maintain patency to sustain a steady flow of urine from the kidney to the
bladder, ureteral stents are implanted after nearly every nephrological procedure
including treatment for urinary incontinence, kidney stones, and renal transplants. [1],
[2], [3] Ureteral stents have had a significant impact in the field of urology, turning many
procedures that would have required overnight stays in the hospital into outpatient
procedures [4]. Despite their popularity, several downsides to using current ureteral stent
technology exist. First, when a stent is implanted for any length of time, encrustation of
the device can occur.[5], [6], [7] Most significantly, ureteral stents always require a
second procedure to be removed. Though time varies based on the procedure, it is rare
for a stent to be implanted longer than 90 days. [8], [9], [10] This removal procedure is
both a loss of time for the urologist and an additional expense for the patient. To date,
however, these problems are yet to be solved by existing stent technologies.

1.2 Anatomy of the Urinary System
The urinary system consists of the kidneys, ureters, bladder, and urethra and its
main function is to remove waste (e.g., uric acid, creatinine, ammonium, ions, sulphates,
phosphates, and oxalates) [11] from the blood stream and convert it into urine. The urine
travels down the ureters into the bladder where it is stored. Voiding of the urine through

1

the urethra takes place by coordinated relaxation of the external urethral sphincter and
contraction of the bladder smooth muscle forcing the urine out of the body. [12]

Figure 1-1 Urinary System
[13]

1.2.1 Kidney
The kidneys (Fig. 1-1) are bean shaped organs that filter waste out of the blood by
1 million tiny units called nephrons. [14] Within each nephron is the glomerulus with
specialized structures called fenestrae that selectively allow small molecules to pass
through and retain larger substances like red blood cells in the blood. This filtrate is
combined with water secreted by the kidney to produce urine. The urine is transported
through a tubule through the inner part of the kidney into the collecting duct. Urine is
then transported by the ureter to the bladder. [12]
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Figure 1-2 Nephron
[15]

1.2.2 Ureters
The ureters are roughly 25 cm in length and allow transport of urine from the
kidney to the bladder via peristalsis. The wall of the ureter is composed of three layers,
the mucosa, muscularis, and adventitia. Unlike other transport tubules such as the GI
tract, the ureter lacks the connective tissue layer known as the submucosa.
The innermost, mucosa layer is further divided into transitional epithelium, which
prevents urine absorption, and the lamina propria, a relatively thick layer of connective
tissue. The mucosa typically exhibits a folded morphology. However, as peristaltic
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waves travel the ureter, the folds can stretch which increases the diameter of the ureter
dramatically. [12] The muscularis responsible for peristaltic motion is composed of two
bands of smooth muscle orthogonally oriented in longitudinal and circular directions.
This muscle contracts in a wave like motion to form boluses of urine that move along the
ureter in the inferior direction. It has been reported that the pressure generated by the
peristalsis can be as high as 1.9 kgf/cm2 [16] The outermost adventitia layer is
composed of aereolar connective tissue and its primary purpose is to anchor the ureter to
the posterior abdominal wall.

Adventitia
Muscularis

Mucosa

Figure 1-3 Histology of the Ureter
(Adapted from [17])
Blood supply to the ureter is provided from the branch of the nearest artery (e.g., renal
arteries, aorta, common iliac, or internal iliac arteries) and drainage is from companion
veins.
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Figure 1-4 Vascularization of the ureter
[18]
The superior region of the ureter is innervated by parasympathetic fibers from the
Central Nervous System (CNX) via the dorsal vagus nerve, while the inferior region is
innervated by the pelvic splanchnic nerves. While not known definitively, it is believed
that this modulates intrinsic pacemaker cells, which cause the regular peristaltic action.
[19]
It has been observed that the ureter has three physiologic narrowings. First,
where the ureter connects to the kidney, is called the ureteropelvic junction. Second,
where it crosses over the iliac vessel. Finally, where it connects to the bladder called the
ureterovesical junction. The ureteropelvic junction and ureterovesical junction are the
location where stones are most likely to be trapped. [20] These three narrowings also
limit retrograde instrumentation such as placement of a ureteral stent.
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1.2.3 Urinary Bladder
The bladder is an organ whose purpose is storage and periodic voiding of urine.
The bladder can contain on average 350 mL of urine before urgency to urinate is felt, but
as much as 700 mL can be retained in adult humans. [21] Due to its folded rugae and
high elastin content the bladder is highly distendable. [22], [23], [24] During storage of
urine, continence is maintained by the external uretheral sphincter. [12]
Backflow into the ureter is prevented by the special anatomical structure of the
vesicoureteral junction. Instead of connecting perpendicular to the bladder wall, the
ureter enters the bladder diagonally and runs 1.2-2.5 centimeters along the bladder wall
(Figure 1-5). [17] When the bladder is filled this segment flattens, thus preventing
backflow of the urine into the ureter.

Vesicoureteral
Junction

Figure 1-5 Vesicoureteral Junction
(Adapted from [25])
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1.3 Ureteral Stents
Ureteral stents are devices that are implanted to physically hold open the ureter
allowing urine to flow. Indications that determine when to use a ureteral stent can be
broadly organized under five main classifications are: 1) Relief of a cancerous
obstruction; 2) Adjunct to stone therapy; 3) Perioperative placement; 4) Management of
urine leak; and 5) Relief of ureteral stricture. The most typical indication for stent use is
as part of kidney stone treatment. [26], [27], [28]
It is worth noting that the terminology for ureteral stents has changed over the
years. Until the 1950s the terms tube, catheter, and retention catheter were adequate to
describe procedures in urology. [29] The first publications on ureteral stents used the
term “splint” perhaps because it was used to immobilize the ureter in a fashion similar to
a leg splint. Researchers often retroactively refer to what was called “splints” as “stents”.
[29], [30] Additionally, there is some confusion between the term “ureteric” and
“ureteral”. The author has found no differentiation between these two terms, though it
appears that “ureteral” is the most common usage. For the purpose of this paper all
descriptions will classified as “ureteral stents”.
The first stent described in literature in 1952 was little more than a silicone tube.
[30] While it provided adequate drainage, it frequently migrated into the bladder. [31]
In 1967, ureter specific stent was designed by Gibbons, who successfully created an
anchor to hold the stent in place in the ureter. The Gibbons stent was barbed on the
exterior to keep it from moving down the ureter and had a “C” shaped bend at the
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proximal end to prevent the stent from moving up the ureter. While initially popular the
Gibbons stent is no longer on the market due to difficulty with insertion. [32], [33]

Figure 1-6 Gibbons Stent
[32]
It wasn’t until the introduction of the double-pigtail and double-J stent
configuration in 1978, that stents were regularly used without experiencing major
problems. [34] Today, numerous materials, coatings, and stent designs have proven to be
more effective in restoring regular flow of urine into the bladder. The two most common
materials used in stent production today are silicone and polyurethane.
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Figure 1-7 (a) Ureteral Stent with double pig tail anchor (b) Cross-section with drainage
hole
[7]

1.3.2 Complications of Ureteral Stents
As ureteral stents usage increases, so too has the incidence of related complications.
While stents are generally considered safe they are not without risk. Complications
pertaining to ureteral stents can be broadly separated into seven categories.

1.3.2.1 Irritative Bladder Symptoms
By far the most common side effect of ureteral stenting is irritative bladder
symptoms, which occurs in up to 80% of patients. [35] Irritative bladder syndrome is an
inclusive term for voiding symptoms, flank and suprapubic pain, incontinence and
hematuria. It is viewed as a manageable side effect and is typically treated with pain
prescription. [3]

1.3.2.2 Urinary Tract Infection
When a stent is introduced to the normally sterile ureter, the risk of infection in the
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urinary tract increases. After implantation, proteins rapidly adsorb to the stent surface,
which enable deposition of minerals and other urine components as well as attachment of
bacteria. The most common bacteria seen in urinary tract infections (UTIs) are
Escherichia coli (E coli), Staphylococcus and Pseudomona. [10] In most patients,
antibiotic prophylaxis is performed, typically in a single dose immediately before the
stenting procedure.

1.3.2.3 Inadequate Relief of Obstruction
Under various situations a stent may not restore urine flow as intended. For
example, loss of flow within hours of insertion may be a result of blood clotting or debris
from a severe infection, both of which are extremely dangerous and require immediate
care. [36] Occlusion can also be a result of extrinsic pressure. Stents of smaller
diameter can be collapsed by pressure from a tumor or stricture. [13]

1.3.2.4 Ureteral Erosion or Fistulization
Ureteral erosion is the most dangerous of all the complications associated with
stents. Although the etiologies are complex and difficult to diagnose, the dominant
symptom of erosion is gross Hematuria. However, by that point erosion has already
taken place. [38] Factors that increase the likelihood of erosion are prolonged stent use,
prior pelvic surgery, cancer and extensive irradiation. The presence of a pulsating
vascular structure, (normal vessel, graft, or aneurysm) to a rigid stent has also been
associated with erosion. [38], [32]
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1.3.2.5 Malposition and Migration
Malposition of the stent may result from human errors during placement although
urologists are recommended to use fluoroscopy. Stents made of stiffer material may
accidentally pierce through the ureter wall resulting in an urinoma or hematoma [32].
The stent that is not pushed all the way to the kidney may cause the anchor to stay
straightened in the ureter instead of curled in the kidney. The force of self-curling can
bury the stent anchor into the wall of the ureter making removal difficult.
Migration of the stent from its placement origin can happen both superiorly into
the kidney and inferiorly into the bladder. Most commonly the stent migrates into the
bladder due to peristaltic motion from the ureter and pressure from urine creation in the
kidney. Instances of this complication have increased recently, likely due to the new
hydrophilic coatings that reduce the friction of the stent. [32]

1.3.2.6 Encrustation
All stents elicit different forms and degrees of encrustation after insertion. The
presence of the stent provides a substrate for the deposition of minerals including calcium
oxalate, struvite, apatite, and uric acid along with organic macromolecules. While all
these can be present, calcium oxalate typically makes up the largest portion of
encrustation. [5] Risk factors for encrustation include stone disease, urinary sepsis,
chemotherapy, pregnancy, chronic renal failure, metabolic or hormonal abnormalities,
and the most important being the indwelling time. [27] The most common location of
encrustation is the proximal end at the anchor that sits in the kidney. This location is
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more prone because the concentration of solutes is higher in the kidney. It has also been
suggested that peristalsis may have a cleaning effect on the body of the stent, and, thus,
encrustation is rare. [6], [27]

1.3.2.7 Urine Reflux During Voiding
Due to the proximal anchor of the ureteral stent sitting in the bladder, the
vesicoureteral valve is forced open by the stent body. During voiding, this forces urine
up the ureter and into the kidney. This can cause pain and increases the risk of infection.
[4][7]

1.3.2.8 Stent Fracture
Stent fracture is becoming increasingly less frequent as materials for stents have
improved over time. However, there is still a risk of fracture. Fracture typically occurs
at the drainage holes (also called fenestrations). [36]

1.3.3 Materials for Ureteral Stents
Many materials have been proposed for use in ureteral stents. The first-generation
of stents were made of silicone. [39] While still considered the gold standard, silicone is
rarely used in ureteral stents without a coating due to its high coefficient of friction. [40]
After silicone, polyethylene was introduced as the material for ureteral stents. Due to the
high risk of fracturing, however, polyethylene is not as widely used today. Finally,
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polyurethane was introduced onto the market. While rarely used alone it has been prized
for its ease of coating and modification. [39], [41] Metal stents also exist in a small
niche for extremely long indwelling times and for very tight strictures.

1.3.3.1 Polymers for Ureteral Stents
Many different polymers have been proposed for use in ureteral stents. While
much research has been done, the two main stent materials remain silicone and
polyurethane. However, within the context of these two materials many modifications
have been performed. Coatings have been added to reduce friction for ease of
implantation and reduce encrustation. [42] Substrate modifications have been performed
to improve material properties such as stiffness and hydrophilicity. [39]

1.3.3.1.1 Polyurethanes
Polyurethane (PU) is a polymer composed of an organic group attached via
carbamate groups (-NHCO2-). Although, it has long been used a stent material with
many different kinds currently on the market, polyurethane has been shown to be more
prone to encrustation than silicone. [43]

1.3.3.1.2 Tecoflex
Tecoflex is an aliphatic PU blended with barium sulfate to provide a high
radiopacity. Tecoflex is a thermoset PU and is used in stents because of its ability to
soften when warmed by the body after stenting. This allows it to be rigid for insertion
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but more flexible after insertion for better patient comfort. Tecoflex stents are produced
by Gyrus ACMI. [44]

1.3.3.1.3 Hydrothane
Hydrothane is a polytetramethylene glycol based alphatic PU produced by
Cardiotech International. The addition of the glycol subunits increases the polymers’
hydrophilicity. When used for stents, hydrothane can be processed without aromatic
groups. This lack of aromatic groups increases biological inertness by reducing
generation of dispersion (van der Waals) forces between the polymer and the proteins
found in urine. [45], [46]

1.3.3.1.4 ChronoFlex
Also produced by Cardiotech International, Chronoflex was developed to be a more
durable PU and studies have shown that it exhibits less environmental stress cracking
than other PUs. [47] This polymer had more hydrophobic properties which suggests it
forms a stable conditioning layer, thus preventing encrustation. [48]

1.3.3.1.5 Percuflex
Produced by Boston Scientific, this polymer is a proprietary olefinic block
copolymer and is another thermosetting PU. Percuflex softens in the body and has better
physical properties than PU. However, encrustation is similar to standard PU. Because
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of the softening affect, these stents are not used in cases of stricture due to extrinsic
obstruction because they are easily compressed. [43]

1.3.3.1.6 Aquavene
Aquavene is produced by Menlo Care Inc. and is a polyurethane blended with
polyethylene oxide. When placed in water, it swells increasing in size, but maintaining
strength. Aquavene is harder in dry conditions and softens rapidly when hydrated which
aids in implantion and patient comfort. [49]

1.3.3.1.7 Sof-flex
Sof-flex is a proprietary polymer developed by Cook Medical that lists
polyurethane as its primary ingredient. It has been used extensively in ureteral stents. It
boasts a very small coefficient of friction because its hydrophilic properties hold water to
its surface. Studies have shown low biofilm formation but increased encrustation of
calcium carbonate. [39]

1.3.3.1.8 Silicone
Silicone is the “gold standard” material for ureteral stents and is composed of
alternating silicone and oxygen atoms. Due to its uniform surface, it is less prone to
encrustation than PU and hydrogel-coated PU. Because of its inertness, it is ideal for
long implantation times. However, silicone is almost never used without some sort of
surface coating because its high-coefficient of friction makes implantation difficult. [43]
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1.3.3.1.9 Silitek
Silitek, produced by ACMI, is a proprietary polyester copolymer made to replace
silicone. It is firm and has a high radial stiffness to resist compression. Studies have
shown that it has an encrustation profile similar to silicone. It has relatively weak coil
retention strength which may make it more likely to migrate. [50]

1.3.3.1.10 C-Flex
C-flex, produced by is a polymer made up of styrene/ethylene-butylene/styrene
block copolymers. It has thermoplastic properties and has been clinically used in stents.
It is comparatively weak when compared to other stent types but is adequate for typical
stenting. [50] Uncoated C-flex stents are sold by Cook medical while Boston Scientific
sells a hydrogel coated stent that lowers its coefficient of friction. However, it has been
shown that the hydrogel coated stents are more prone to encrustation. [43]

1.3.3.2 Coatings of Ureteral Stents
Various stent coatings have been explored for prevention of encrustation and
bacterial adhesion or for easier implantation by decreasing surface friction. In addition,
many studies have investigated the release of antibiotics and other chemicals from
hydrogel coating on stent surface.
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1.3.3.2.1 Hyaluronic Acid (HA)
HA is a glycosaminoglycan that inhibits the nucleation, growth, and aggregation of
salts. [51] For this reason, it has been explored as an anti-encrustation coating. Plasma
treatment has been used to covalently bond HA to polyurethane stents. An in vitro study
showed that HA coated stents have a lower rate of encrustation than silicone stents. [52]

1.3.3.2.2 Heparin
Heparin is a highly sulfated glycosaminoglycan that is known most as an
anticoagulant. Heparin has the highest negative charge density of all known biological
molecules. [53] Heparin coated stents have been shown to prevent biofilm formation in
human pilot studies over a 6-8 week time period. This is attributed to heparin’s
electronegativity repelling proteins and microorganisms. [54]
Heparin can be adsorbed to the stent surface, incorporated into the stent material, or
covalently bonded to the surface. Because of the risk of leaching and limited
effectiveness with the first two approaches, covalent bonding is considered to be the most
effective method. [55]

1.3.3.2.3 Polyvinylpyrrolidone (PVP)
PVP is a water absorbing polymer used as a coating for ureteral stents because of
its excellent wetting properties. PVP provides a smooth, soft, water coating that
minimizes difficulties during insertion. Adherence of bacteria and encrustation were
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found to be less on PVP coated PU than uncoated PU because the water layer prevented
bacterial adhesion. [56]

1.3.3.3 Metal
Metal stents are not used for routine stenting. However, metallic stents are used for
instances when longer indwelling times are required. [57] Metallic stents are also much
cheaper to manufacture. A 2010 study was performed in which 15 metal stents were
placed in 13 patients to manage obstruction. Their health care costs were tracked for
almost two years and then compared to national averages. It was found that the annual
cost of metallic stenting was $11,183 while the average yearly costs for polymeric stents
were $23,999. From this small sample it appears that metallic stents are an excellent cost
saving measure. [58]
There have been a variety of metals explored in the context of ureteral stents. A
self-expandable polytetrafluoroethylene-covered nitinol stent has been successfully used
to manage strictures. In 2003 29 PTFE covered nitinol stents were implanted. The stent
did not encrust and the PTFE covering greatly prevented hyperplasia. However, it had
about a 22% migration rate which may explain why it has not seen clinical use since then.
[59]
1.3.3.4 Biodegradable Polymers for Ureteral Stent Applications
Although no ureteral stents made entirely of biodegradable polymers are currently
available on the market these polymers have gained interest due to their resistance to
encrustation and the elimination of a stent removal procedure. [60] Following are
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examples of the polymers that have been studied within this scope.

1.3.3.4.1 Polylactic Acid (PLA)
PLA (or polylactide) is a thermoplastic biodegradable aliphatic polyester, which
can be processed into a fiber or into a film. [61] Due to the chiral nature of lactic acid,
PLA can be further subdivided based on the D or L isomer, changing the naming
convention to PLLA or PDLA. [62]
Lumiaho et al. explored self-expanding Poly-L-D-lactide as a material to fabricate a
ureteral stent in a 2009 study. [63] Briefly, PLA was mixed with 20 wt% barium sulfide
and extruded to create a fiber with 0.35mm in diameter. The fiber was then wrapped
around a mandrel to create what the author calls a double helix structure with final inner
and outer diameters of 1.3mm and 0.6mm, respectively. Following gamma sterilization,
the PLA stents and control, 3.8F Double-J C-Flex® stents, were implanted in 6 dogs
each. Although the PLA stent provided adequate renal output, fragments of the stent
remained imbedded in the ureter after 12 weeks. [63] For this reason, in the subsequent
studies the author switched from PLA to Poly Glycolic Acid. [64]
In a separate study, Gang et al. also explored the use of PLA as a ureteral stent
material, with a special emphasis on relieving hydronephrosis caused by war injury. [65]
Briefly, 50mm long stent segments were constructed by forming 50:50 PLLA/PDLA into
a fiber and winding into a helical shape with 0.8mm and 1.4 mm inner and outer
diameters, respectively. In vitro testing demonstrated that the stent took 10 weeks to
degrade in synthetic urine. An in vivo canine model study demonstrated that the material
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did not start degrading until day 80, and by day 120 only a few fragments were retained
in the ureter. When injured unstented ureters, and injured stented ureters with the novel
PLA stent were compared, it was found that the stents did improve urine flow. [65]

1.3.3.4.2 Polyglycolide (PGA)
PGA (Polyglycolide) has been shown degrade slowly into irregular sized
fragments. Since PGA is brittle and mechanically inadequate, it has been used as a block
copolymer with other biodegradable polymers for ureteral stent applications.
In a 2011 study, Lumiaho et al. would PLGA wire over a mandrel to fabricate a
40mm long stent with 4mm outer diameter. [63] Owing to its viscoelastic memory, the
stent could expand in diameter up to 40% when heated from room temperature to body
temperature.
An animal study on 8 pigs was performed to compare PLGA stents to the common
double J stent. A small cystotomy was performed on both ureters and the left ureter was
stented with PLGA stent segments while the right ureter was stented with double J stents.
The type of double J stent material was not reported. After 4 weeks, 6 of the 8 PLGA
stents showed no reflux, while 2 showed minor reflux. All double J stents showed some
type of reflux. [63]

1.3.3.4.3 Temporary Ureteral Drainage Stent by Boston Scientific
In 2002, Boston Scientific began trial of a biodegradable stent with a product name,
Temporary Ureteral Drainage Stent (TUDS). It was made of a proprietary alginate based
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polymeric material that was designed to last 48 hours before being fully degraded in the
body. It was successfully tested on 18 patients in a phase I clinical trial. All material had
been degraded by 4 weeks and the only adverse effect was one stent that migrated into
the bladder.
Because of the success of the phase I trial, a phase II trial on 88 patients was
performed. The stents were eliminated from the ureter at a median of 8 days and from
the body at a median of 15 days. For the majority of patients (78.2%) the stent provided
effective stenting of the ureter for 48 hours. Unfortunately, after 3 months stent
fragments remained in 3 patients and surgical intervention was required. Due to concern
about the fragments, the TUDS never made it to market. [66]

1.3.3.4.4 Uriprene Ureteral Stent by Poly-Med, Inc.
The most recent development in biodegradable technology is a substance called
UripreneTM. Uriprene is a biodegradable polymer composed of L-lactide, glycolide, and
copolyester components. The material was tested in a porcine model in 2008 and was
found to degrade in 7-10 weeks. Though the stent provided excellent drainage, it lacked
axial rigidity making it difficult to advance up the ureter.
The Uriprene stent was improved to degrade faster and provide better axial rigidity.
In 2009, the stent was again tested in a porcine model. The degradation time was
decreased so that 80% of the stents degraded within 2-3 weeks and 100% of stents were
eliminated by week 4. The stent was also very biocompatible in histology and provided
adequate drainage. The Uriprene stent currently awaits clinical trials. [67]
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2. RATIONALE
Approximately 92,000 ureteral stents are implanted every year in US for the
treatment of kidney stones, kidney transplants, and urinary incontinence. [68] Although
many new materials have been studied for use in ureteral stents, the majority are still
made of polyurethane and silicone. While incremental improvements have been made to
the design of stents to make implantation easier and reduce encrustation, the basic
ureteral stent design has not changed since 1978 when the double J stent debuted. [34],
[67] The two main issues continuously facing ureteral stents are encrustation and the
need for a removal surgery. Encrustation occurs on all stents at varying degrees and is
especially problematic in longer-term use stents. [27], [52] Removal surgery is a large
cost additive ($1,131.27 in hospital fees and $149.36 in service fees. [69]) and also
requires patient compliance. Occasionally, patients do not return for the removal surgery
and the stent that remains in the body for longer than intended can cause renal failure and
even death. [70]–[72] A biodegradable stent could solve both these problems as it has
been shown that biodegradable materials reduce encrustation and can safely be removed
from the body. [73], [74] In addition, a biodegradable stent could reduce the cost of
stenting procedure by as much as 37%.
The goal of this master’s thesis project is to develop a biodegradable ureteral stent
that is equivalent in effectiveness to stents on the market. The main design / performance
criteria included: 1) variable length/diameter; 2) easily implantable using existing
techniques; 3) provide adequate flow of urine; 4) biocompatible and reduced
encrustation; 5) flexible for patient comfort; and 6) degrade in a controlled manner within
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6 weeks to encompass most uses.
Following preliminary screening of various biodegradable polymers,
polydioxanone (PDO) was selected as a material of choice to fabricate our biodegradable
ureteral stent. PDO was chosen because it was easily processed to gain the desired
mechanical properties. Additionally, PDO has exhibited lower inflammation rates when
compared to sutures made of Polylactic Acid and Polyglycolic Acid. [75], [76] PDO is
most commonly used in sutures (PDS, Ethicon), though it has been studied for use in
vascular stents, tracheal stents, and other applications. [77], [78] It is a monofilament
homopolymer with consistent morphology and high purity.[79], [80] In the present
study, commercially available PDO sutures were obtained and fabricated into a tubular
structure to meet the functional requirements of ureteral stents. The project was divided
into the following specific aims.

Aim 1: Establish a reproducible process to alter the characteristics of polydioxanone for
use as a stent.

Aim 2: Characterize the stent by quantifying its degradation time, flow rate, flexibility,
and radial strength and verify that these parameters are adequate for physiological
conditions.
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Aim 3: Compare the chemical and physical characteristics of processed and unprocessed
PDO to determine the mechanism that changes the material properties of the polymer
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3. MATERIALS AND METHODS
3.1 Fabrication of Novel Stent
The spiral-shape stent was created by tightly winding a commercially available PDO
suture (PDS, size 3-0 (0.2 mm diameter) Ethicon) around a brass rod (diameter = 3.15
mm, Ace Hardware) by hand. Approximately 1m of suture is required to make a 6cm
sample segment. When necessary, a custom rod extension with curls at either end was
used to create J-shape anchors modeled after stents currently on the market (Figure 3-2).
The ends of the suture were secured onto the rod using stainless steel clips before
annealing in an oven (Fisher Scientific) at 100 °C for 24 hours. The stents were then
quenched in a deep freezer (Isotemp Base) at -80 °C for 30 minutes.

Following removal

from the rod, the stents were trimmed of the excess suture and placed in a desiccator
immediately to prevent degradation from moisture. All tests were performed within one
week of stent creation to prevent any partial degradation of the material. Test specimens
that have been annealed and then quenched are referred to as “processed” and all
untreated PDO suture is referred to as “unprocessed” in the balance of this document.

Figure 3-1 Detail of Coil Design Demonstrating Tube Flexibility
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Figure 3-2 Initial Design with Double J anchor

3.2 Designing of Stent Sheath for Novel Anchoring Method
Initial attempts to fabricate a biodegradable ureteral stent were modeled current
stents on the market and utilized a standard double J anchor (Figure 3-2). However,
implantation using the standard guide wire and push catheter method was very difficult
due to the spiral structure creating a high surface roughness. Additionally, initial
experiments (in accordance with ASTM standard F1828) found that the anchor strength
with the J-anchor design (Figure 3-2) was very low, (<0.03N).
To improve on these limitations, a novel stent implantation and anchoring
method, was designed. Specifically, the new anchoring method relied on radial
expansion of the stent (I.D 3.15mm and O.D. 3.55mm) during implantation upon release
from a silicone sheath (C Flex L/SO.D. 7mm and I.D. 3.1mm). To place the stent inside
the sheath, one end of the stent coil was glued to a steel wire and the free end was twisted
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until the diameter was less than the inner diameter of the sheath. The stent was fully
placed within the sheath by feeding the wire through and the glued end was snipped to
allow the stent to uncoil in the sheath (Figure 3-3).

Figure 3-3 Sheath and Stent Implantation Scheme

3.3 Characterization of the Novel Degradable Stent
3.3.1 Degradation of PDO
The mass loss due to degradation was determined by measuring the stent weight
change after subjecting the stent to near physiological conditions using a customdesigned ureteral flow simulator. The ureteral flow simulator was kept in a climate
controlled room at 37°C to imitate human body temperature. Deionized water circulated
through the simulator at 4 mL/min to match the standard flow rate of a ureter. The water
resevoir was changed each week to prevent accumulation of degradation byproducts.
The flow circuit (Figure 3-4) consisted of silicone tubing, a peristaltic pump
(Fisher Scientific Mini-pump), a 1 L water reservoir, and clear polyethylene tubes. After
recording the initial weight, stent samples (6cm long, O.D. 4.15 cm) were placed in
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polyurethane tubes (inner diameter of 1.905 cm) to mimic implantation in a ureter. Each
week the water in the reservoir was changed to limit the build up of solute concentrations.
The stent samples were then removed from the flow circuit and dried in a desiccator
under vacuum for 24 hours before weighing to determine mass loss.

Figure 3-4 Flow Degradation Experimental Setup

3.4 Characterization of Processed PDO
3.4.1 Thermogravimetric Analysis
Thermogravimetric Analysis (TGA) was used to determine the effect of the
annealing process on change in mass of the stent. Briefly, after purging with nitrogen, a
4.22 mg sample was subjected to temperature increases at a rate of 20 °C per minute
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starting at at 23 °C (room temperature) until the sample reached 600 °C using TA
Instruments Model 2950.

3.4.2 Differential Scanning Calorimetry
First heat, Differential Scanning Calorimetry (DSC - TA Instruments DSC model
2920) was used to determine the effects of the annealing process on the melting point and
crystal structure of PDO.

Small (roughly 5mg) samples of both unprocessed and

processed sutures were subjected to an increasing temperature sweep from -75 °C to 150
°C at a heat rate of 20 °C per minute.

3.4.3 Flexure Testing
Flexural rigidity of unprocessed and processed PDO suture samples was
quantified using a cantilever deflection test adapted from ASTM D747-10. Straight
samples (6 cm in length) were clamped on one end so that 5 cm of sample extended
horizontally and a known weight of 1.025g was hung on the free end. The angle of
deflection in radians was measured and the stiffness was calculated using the following
equation.
𝐹𝐿2

𝜃 = 2𝐸𝐽. (Eq.# 1),
where F is the force exerted due to gravity, L is the length of the sample, E is the
modulus of elasticity, J is the polar second moment of area.
For a rod with circular cross sectional area such as the suture, J can be given as
𝜋

𝐽 = 2 𝑟 4 (Eq.# 2),
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where r the radius of the circular corss section. For this test, r was measured as 0.305
mm.

3.4.4 Fourier Transform Infrared Spectroscopy
To determine chemical composition, Fourier Transform Infrared Spectroscopy
(FTIR) was performed on uprocessed and processed PDO suture samples. A small
shaving (≈1 g) of each material was made with a stainless steel razor blade to create a
flat surface for adequate contact with the focusing crystal. The samples were tested using
a Thermo-Nicolet Magna 550 FTIR Spectrometer with a Thermo-SpectraTrech
Endurance Foundation Series Diamond ATR. The resulting absorbance curves were then
analyzed using standard absorbance tables [4] to verify the chemical purity of the initial
PDO samples and to verify that there was no chemical change during processing.

3.4.5 Wide Angle X-Ray Scattering
Wide angle X-ray scattering with Cu Kα1 radiation at λ = 1.54060 Å was
performed on both unprocessed and processed PDO suture samples using a Rigaku
Ultima IV X-ray diffractometer to compare the degree of crystallinity. To allow
consistent absorption of X-rays, suture was cut into pieces of varying length and arranged
in parallel on the circular aluminum sample pan to create a solid, consistent sample layer.
Likewise, processed PDO samples were created in a straight orientation instead of the
normal “coiled” orientation and arranged into a solid layer. After initial scanning at an
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angle from 5°-60° for 3 hours, the peaks of interest were identified and a second scan was
run from 5°-35° for 3 hours.

3.4.6 Inherent Viscosity
To determine the molecular weights of the processed and unprocessed PDO
suture samples, the inherent viscosities were determined. Processed and unprocessed
PDO （0.25m g each） was dissolved in 15 mL of hexafluoroisoproponal (Oakwood
Chemicals) with agitation at room temperature for 24 hours. The PDO solutions in
hexafluoroisoproponal were then decanted into size I Ubbelholde capillary viscometers
(Cannon Instruments) and allowed to equilibrate in a water bath at 25 °C for 10 minutes.
The inherent viscosity was measured by viscometric analysis according to ISO 16281:2009.
Briefly, before testing the PDO samples, the viscometer was rinsed with HFIP to
remove any potential contamination. Ten mL of HFIP was then decanted into the
viscometer and nitrogen was used to force the HFIP up the viscometer capillary. A
stopwatch was used to measure the time it took for the HFIP to flow through the
viscometer capillary while recording the time it took. This process was repeated 5 times
and the average time was calculated to establish a “Sample Efflux Time”. After the HFIP
was removed and the viscometer was dried by flushing with nitrogen, the PDO solution
was tested in the same manner to determine a “Solvent Efflux Time”. Using the Sample
Efflux Time and the Solvent Efflux Time, the Relative Viscosity (Rel, Eq. #3) and the
inherent viscosity were calculated (Eq. # 4).
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Rel = Sample Efflux Time  Solvent Efflux Time (Eq.# 3),
Inh = ln(Rel)  Solution concentration (in g/dl) (Eq. # 4.)

3.5 Validation of Implantation Method
Fresh porcine ureters were harvested on site at Snow Creek Meat Processing
(Seneca, SC) and stored in 500mL of saline solution on ice and transported to the
laboratory for use on the same day. After a 6 cm long stent was packaged in the silicone
sheath (as described in 3.2) the entire structure was placed on the guide wire. The guide
wire was threaded through a 6 cm long ureter segment and the sheath was slowly pushed
into the ureter using a push catheter. Simultaneously, the sheath was retracted to force
the stent out of the sheath. Upon leaving the sheath, the stent uncoiled to its original
diameter and anchored itself in the ureter (Figure 3-5). Upon implantation the stent was
used for anchor strength and flow testing.

Figure 3-5 Two Implanted Stents with Unimplanted Stent for Comparison
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3.5.1 Anchor Strength Testing
Initial anchor strength testing was attempted via an adaptation of ASTM F182897 using MTS Synergie 100 with 10N load cell. The stent was implanted into a ureter
segment as described in section 3.5 The specimen was submersed in a reservoir with 0.5
L of DI water at 37 °C during the test. The top of the stent was grasped by the top grip
and the ureteral segment was attached to the bottom grip. The stent was pulled out of the
ureter at rate of 20mm/min. The maximum force detected was given to be the anchor
strength. However, during the test, it was observed that the stent uncoiled and elongated.
Additionally, a very large extension was required for the stent to pull out of the ureter and
the results varied greatly.
To provide a more repeatable and physiologically relevent test, the method of
attaching the stent to the grip was modified. All experimental conditions were the same
except a 12-gauge steel wire was threaded through the stent and glued with epoxy to the
bottom end of the stent. (Figure 3-6) The “push wire” was then attached to the top grip
of the MTS machine and the ureter segment attached to the bottom grip. The wire was
pulled at a rate on 20 mm/min, applying force to the bottom of the stent, until the stent
became dislodged from the ureter.
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Figure 3-6 Stent Anchor Strength Experimental Setup

3.5.2 Flow Rate in a Stented Ureter
The maximum flow rate of water through a stented ureter was measured to verify
that the stent would not impede drainage of the kidney. To test this, a 3.9 cm long stent
segment was placed in a 4 cm long ureter (as described in section 3.6) and a fixed volume
(50 mL) of DI water was flowed through the ureter while the time was recorded. This
process was repeated 10 times to obtain statistically meaningful data.

3.6 Radial Strength Testing
To determine the radial strength of the stent, a novel testing device was designed,
assembled, and calibrated. A 6 cm long flexible polyethylene sleeve with a closed end,
was attached to a 500 mL rigid polyethylene canister such that the inside of the sleeve
was exposed to atmospheric conditions while the outside of the sleeve was exposed only
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to the interior of the chamber. A 6cm stent segment was placed in the flexible sleeve. A
12V air pump (Airpo D028B) was connected to pressurize the chamber and to apply a
radial force uniformly across the stent encased in the sleeve (Figure 3-7).

Figure 3-7 Diagram of Radial Strength Testing Device

To monitor the pressure in the chamber, an Arduino Blue Tooth Microcontroller
(Smart Projects, Italy) with a custom program (appendices) and an attached Adafruit
BMP085 pressure sensor (Sparkfun, Boulder, CO) were used (Figure 3-8). During
testing, the pressure was recorded in realtime via a bluetooth connection to a computer
(Apple, Macbook pro) and deformation of the stent was monitored visually. The pressure
data were converted to radial force by multiplying the pressure by the area of the sheath.
The maximum force exerted on the stent was determined and reported as the radial
strength of the stent.
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Figure 3-8 Completed Radial Strength Testing Device

3.7 Statistical Analysis
All results are expressed as the mean ± standard deviation of the mean . All
statistical analysis was performed using single factor analysis of variance (ANOVA).
Differences between the means were determined using least-significant difference with a
significance level of α=0.05. Error bars shown are the standard deviation of the mean.
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4. RESULTS

4.1 Characterization of Stent Degradation
4.1.1 Mass Loss of Stent due to Hydrolytic Degradation
The mass of all the stents remained nearly constant (0.14g ± 0.01g p= 0.14) during the
three week flow circuit degradation test. (Figure 4-1) After four weeks, however, the
stent had crumbled and small stent fragments (<1g) had been flushed into the water
reservoir. The degradation test was then terminated at that time point.

Figure 4-1 Average Mass Loss of Stent Over Time
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4.2 Physical Characterization of Stent
4.2.1 Thermogravimetric Analysis of Processed Stent and Unprocessed Suture
To determine the thermal stability of the processed and unprocessed PDO suture,
TGA was performed. (Figure 4-2) The results of TGA indicated that both samples
started losing mass at 200 °C and reached 0% mass at approximately 350 °C. However,
the processed stent started losing mass at a faster rate than the unprocessed suture. This
indicates that stent is degraded and has lower molecular weight polymer chains which are
more easily volatilized. Holding the stent at 100 °C kept the stent showed no change in
mass.
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Figure 4-2 Plot of Thermogravimetric Analysis of Annealing Process Over 6 Hour
Period
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4.2.2 Differential Scanning Calorimetry
Differential scanning calorimetry (DSC) was used to determine the potential
change in crystallinity of the polymers due to annealing by calculating the enthalpy of
melting. First, the DSC established that each sample was a single material and phase
(semi-crystalline) as shown by the single peak (Figure 4-3). The melting temperature
(Figure 4-4) was determined as the temperature at which maximum heat flow was present
represented as the lowest point on the curve. The enthalpy of melting for each material
(Figure 4-5) was determined by integrating the area of each melting peak in DSC plots.

Figure 4-3 Representative Differential Scanning Calorimetry Curve of Processed Stent
and Unprocessed Suture
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*

Figure 4-4 Melting Temperature of Processed and Unprocessed Suture (Data are mean ±
standard deviation *p= 0.001 analyzed by ANOVA, n=4)

The processed stent exhibited a significantly (p=0.001) greater average melting
temperature (111.89±2.01 °C) compared to that of unprocessed suture (102.32±0.50 °C)
(Figure 4-4). The enthalpy of melting of the processed stent (105.19±16.10 J/g) appeared
greater than the unprocessed suture (92.68±9.30 J/g) (Figure 4-5). However, the variance
of the enthalpy of melting values was high enough such that they cannot be considered
statistically different. The increase in melting point indicates that the material is gaining
crystallinity post processing.
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Figure 4-5 Enthalpy of Melting of Processed and Unprocessed Suture (Data are mean ±
standard deviation p= 0.308, analyzed by ANOVA n=4)

4.2.3 Fourier Transform Infrared Spectroscopy
Fourier transform infrared spectroscopy (FTIR) was used to determine the
potential chemical change of PDO underwent any chemical change during the 24 hour
annealing process.
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Figure 4-6 Chemical Structure of Polydioxanone

The results of FT-IR revealed the presence of the single ketone peak at 1700 cm-1
for both unprocessed and processed suture samples which matches the expected structure
(Figure 4-7). The multiple peaks in the 1000-1200 region verify the presence of multiple
ether groups (Figure 4-7) and their identical locations indicated that chemical structures
were not influenced by the heat processing.
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Figure 4-7 Representative FTIR Curve of Processed Stent and Unprocessed Suture

FT-IR results for processed stent and unprocessed suture showed similar peaks after 6
months of storage indicating that no chemical change in polymer took place over this
time period. The lack of additional peaks shows that there was no contamination with
other materials during storage.

4.2.4 Wide Angle X-Ray Scattering
Wide Angle X-Ray Scattering was used to determine the relative amount of
crystallinity in unprocessed and processed sutures. The initial “scan” between 5 and 60
degrees revealed peaks at roughly 23 degrees, 38 degrees, and 45 degrees. (Figure 4-8)
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The peaks at 38 degrees and 45 degrees were known historically to be a result of
diffraction from the aluminum sample pan and were not studied. The peak at 23 degrees
was deemed the intensity peak of PDO.

Figure 4-8 Initial “Scanning” for Peaks Using WAXS

The peak of interest was scanned with a greater intensity (Figure 4-9). While
unprocessed suture exhibited a major peak of 4512 at 21.62 deg and a lesser peak at
21.88 deg, the processed stent exhibited a peak of 4953 at 21.88 deg and 23.60 deg.
(Figure 4-10), this corresponds to 9% increase in intensity from the suture to the stent.
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Figure 4-9 Representative Wide Angle X-ray Scattering Curve of Processed and
Unprocessed Material

4.2.5 Viscometry
To determine the relative change in molecular weight of PDO sutures due to
heating at 100 °C for 24 hours to fabricate stents, viscosity measurements of the
unprocessed and processed polymers were compared and the results are shown in Figure
4-10. The average kinematic viscosity of the unprocessed suture, 1.58±0.07 dL/g, was
significantly higher (p=0.002) compared to that for processed stent, 1.38±0.07 dL/g. This
indicates that the molecular weight of the suture is higher than that of the stent.
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Figure 4-10 Comparison of Kinematic Viscosity of Processed and Unprocessed Material
(Data are mean ± standard deviation p=0.002, analyzed by ANOVA n=5)
4.3 Mechanical Characteristics
4.3.1 Flexural Stiffness
Flexural stiffness of processed and unprocessed suture was quantified by
deflection testing 6, 12, and 24 hours after processing of the material. The flexural
stiffness of the original suture material determined from the deflection test was 47.9±5.8
MPa with no processing time, 50.3±4.0 MPa after 6 hours, 58.74±4.57 MPa after 12
hours and 65.5±3.8 MPa after 24 hours of processing. This represents an increase in the
stiffness by 27%, during the standard stent processing time.
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Figure 4-11 Flexural Stiffness of PDO at Increasing Processing Times (Data are mean ±
standard deviation p=0.011, analyzed by ANOVA n=5)
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4.3.2 Flow Rate of Stent
The average flow rate of deionized water through a 3.9 cm stent segment placed
in a porcine ureter was 1.74±0.55 mL/s under the test conditions of the present study
(Table 4-1).

Average (+/Trial 1 [mL/s]

Trial 2 [mL/s]

Trial 3 [mL/s]

SD) [mL/s]

Run 1

1.57

1.66

1.00

1.41±0.36

Run 2

2.12

2.62

2.43

2.39±0.25

Run 3

2.26

1.24

1.39

1.63±0.55

1.98±0.29

1.84±0.58

1.61±0.60

1.74±0.55

Average (+/SD)

Table 4-1 Flow Rate through Explanted Porcine Ureter with 3.9 cm Long Stent Segment

4.3.3 Radial Strength
In testing with the custom device that applied increasing radial compression, the
stent withstood a pressure of 30 KPa without breaking or buckling. (Figure 4-12).
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Stent Axial Pressure Test
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Figure 4-12 Radial Pressure Over Time

4.3.4 Anchor Strength
Initial testing where the stent was “pulled” from the top was found to be inconsistent
with an average force of 0.06±0.06 N for a 3.0 cm segment. (n=3). A representative
curve is shown in Figure 4-13. The average anchor strength of a stent in a porcine ureter
using the method where the stent was “pushed” from the bottom was found to be
1.09±0.26 N for a 3.9 cm segment (n=3). (Figure 4-14) This anchor strength would be
substantially larger for a full length stent, and estimated at 7.82 N for a standard 28 cm
long stent.
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Figure 4-13 Representative Curve of Force vs Extension of an Implanted Ureter with
“Pull” Anchor Method
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Figure 4-14 Representative Curve of Force vs Extension with “Push” Anchor Method
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5. DISCUSSION
Approximately 92,000 ureteral stents are implanted every year in US for the
treatment of kidney stones, kidney transplants, and urinary incontinence. [68] Although
many new materials have been studied for use in ureteral stents, the majority are still
made of standard plastics such as polyurethane and silicone. While incremental
improvements have been made to the design of stents to make implantation easier and
reduce encrustation, the basic ureteral stent design has not changed since 1978 when the
double J stent debuted. [34], [67]
The two main issues continuously facing ureteral stents are encrustation and the
need for a removal surgery. Encrustation occurs on all stents at varying degrees and is
especially problematic in longer-term use stents. [27], [52] Removal surgery is a large
cost and also requires patient compliance. Occasionally, patients do not return for the
removal surgery and the stent that remains in the body for longer than intended can cause
renal failure and even death. [70]–[72] A biodegradable stent could solve both these
problems as it has been shown that biodegradable materials reduce encrustation and can
safely be removed from the body. [73], [74]
The goal of this thesis project was to design a stent that solves many of the
difficulties presented by the current stents on the market. In pursuit of this goal, a novel
stent was fabricated by heat-treating a commercially available PDO surgical suture and
shaping it into a coiled tube. To test its performance, the present study characterized the
stent’s degradation profile, chemical composition, and mechanical properties.
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5.1 Design Criteria and Innovative Features
5.1.1 Spiral Structure
Standard biodegradable polymers such as, PDO, PGA, and PLA are too stiff to be
used in a solid walled stent. The spiral design was created in an attempt to utilize these
polymers to create a structure that is both radially stiff and has sufficient axial flexibility.
The stent needs to be radially stiff to hold open a lumen that would otherwise be closed
due, for example, to inflammation, structure, pressure from a tumor, or a naturally
occurring stricture. The axial flexibility is required for the stent to accommodate the
sharp angle from the urethra into the ureter and to improve the patient comfort as
movement at the waist, such as sitting causes the ureter to bend.

5.1.2 Polydioxanone as Material Choice
In the present study the polydioxanone (PDO) suture was annealed and then
quenched to create a stiff material that holds the coiled structure with the desired
flexibility and provides radial strength. The annealing temperature 100 °C was chosen
based on the melt point at roughly 110 °C and the quenching at -40 °C greatly controlled
the process and polymer’s crystallinity. PDO was chosen as the ideal material because its
shape setting allows the polymer to maintain the stent in coiled shape. Additionally,
PDO was ideal for this application because it has a degradation profile in line with that
desired in the ureteral stent application. It has been shown to exhibit a strength loss after
about 15 days with full degradation occurring by 80 days. [81] This was confirmed by
the degradation data obtained in the present study.
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5.1.3 Implantation Method
The standard ureteral stent implantation begins with the urologist guiding a wire
into the urethra, though the bladder, and into the ureter. A ureteral stent is placed on the
guide wire and is pushed into the ureter with a push catheter. The guide wire and push
catheter are then removed allowing the j-shape anchors to curl in both the kidneys and the
bladder to keep the stent in place. However, because of the spiral structure of the stent,
this implantation method could not be used. Pushing on the end of the stent would cause
it to expand and increase its diameter prior to entering the ureter. To this end, a sheath to
hold the stent in place during implantation was developed. A stent segment would be
twisted to reduce its diameter and packaged inside the sheath. Once implanted in the
ureter, the stent could be pushed out of the sheath with a push catheter and recoiling
action would ensure anchoring in position. In the present study, a 3.9 mm stent segment
was successfully implanted in vitro in a porcine ureter with this method. However, it was
discovered that removal of the stent, via the push catheter, from the sheath into the ureter
was very difficult by hand. This is because the stent was anchored in the silicone due to
its tighter coil. A sheath made of a smoother material would allow the stent to more
easily be forced out. While the inclusion of the sheath in the implantation procedure does
add some complexity, it does provide some benefits.

5.1.4 Benefits of Novel Anchor Method
The entirety of the coiled stent comes in contact with the ureteral wall as means of
preventing stent migration instead of the conventional J-shape anchors on the distal
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(kidney) and proximal (bladder) ends. This provides benefits over the standard design.
First, a standard double J stent requires the stent to be long enough for the ureter to
extend and not contact the anchors. The downside to this is that with the ureter at a
shortened position, the stent extends well past the end of the ureter into both the kidney
and bladder. Typically, an implanted stent is at its longest in the supine position and
compresses and shortens by approximately 2.1 cm (1.8 to 3.9 cm) between standing,
bending, and sitting positions. [82] During these periods the stent can press against the
top of the kidney or the base of the bladder, which causes severe pain or feelings of
urgency. The proposed coiled stent design allows the stent to expand and contract as
needed, like a spring, without going into the bladder or into the kidney.
Additionally, the removal of the proximal anchor should allow the stent to sit
above the vesicoureteral junction. This should prevent the
Finally, it has been demonstrated that the distal anchor that sits in the kidney is
most prone to encrustation. [71] Thus, it is believed that the omission of distal anchor
will provide less opportunity for degradation as there will no longer be material present in
the more solute concentrated environment of the kidney.

5.2 Mechanical Characterization
5.2.1 Effects of Annealing on Flexural Stiffness of PDO Suture
Flexural stiffness was determined via cantilever bend test adapted from ASTM
D747-10 and used as an indicator of the changes in the stent material due to annealing.
The material was found to increase in stiffness by 27% (Section 4.3.1, Figure 4-11),
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which is believed to be due to the increase in crystallinity. This is because the polymer
chains are more ordered and thus share dispersion forces (also known as Vander Waals)
more than an amorphous material. This increase in dispersion forces causes the chains to
resist movement which equates, on a macro scale, to an increase in stiffness. [83] The
increase in the stent stiffness was a desired feature to withstand ureteral force and to
allow the stent to maintain its shape.

5.2.2 Radial Strength
The ASTM standard test for ureteral stent radial strength requires compression
between two parallel platens and not applicable for our helical stent design because of its
geometry. To reflect physiological loading condition the where the peristaltic contraction
forces of the ureter would be placed from all sides, a new test method was developed.
Our stent withstood pressure up to 30,000 Pa without any buckling or fracture. This is
much higher than the reported maximum peristaltic pressure of 5000 pa from the ureter,
indicating that the stent has adequate radial strength. This would be analogous to the
result of ASTM F 1828-97 Standard Specification for Ureteral Stents. [84], [16]
Ureteral stents currently on the market are typically made of silicone or
polyurethane. These polymers can be molded into a continuous tube and provide enough
radial stiffness to maintain patency. However, because they are composed of a single
polymer, ensuring the stiffness in the radial directions also causes high stiffness of the
stent in the axial direction. While the stents are flexible enough to be implanted, patient
discomfort is frequently reported. [85] In addition, a soft material is more likely to
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accidently kink when bent such as when the implanted stent shifts from patient
movement. Thus, it is believed that the combination of stiff, annealed PDO with the
spiral design will provide better patient comfort.

5.2.3 Flow Rate
The fluid flow rate through the biodegradable stent was measured using water and
a stent segment implanted vertically in a straight porcine ureter. This would correspond
with stent implanted while a patient is sitting or standing. The results demonstrated that
the average flow rate of urine through the ureter with the implanted stent segment was
1.74±0.55 mL/s (Section 4.3.2, Table 4.1).
The standard flow rate of urine through a ureter varies drastically depending on
hydration and patient anatomy but it is typically derived from the standard production
rate of urine. In the urinary system, urine is produced in the kidney at a gradual rate
where it is stored in the bladder for voiding. Thus, an average value for the flow rate is
typically found by averaging the total measured urine output of the body over a given
time. This yields a flow rate of 0.008-0.167 mL/s for the average flow rate of urine
through the ureter. [7], [86] Because our stent is capable of allowing urine to flow at a
rate approximately 10 times that the reported values, it is believed there will be adequate
draining post implantation.
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5.2.4 Anchor Strength
Our initial attempt to test the anchor strength of an implanted stent was
unsuccessful as the stent exhibited a very low anchor strength with high variability
0.06±0.06 N. Additionally, instead of the expected behavior of the stent pulling out of
the ureter, the stent elongated to over twice the normal length and slipped out of the
ureter slowly. This resulted in an inconsistent force vs deflection curve (Figure 4-13),
with each ring slipping out and creating sharp increases and decreases in measured force.
Finally, after pulling free from the ureter, the stent sprang back into shape, providing the
negative force seen at the end of the curve. This is not believed to accurately represent
the mode in which an anchored stent would become dislodged in the body. Stent
migration is predominantly toward the bladder and is a primarily due to backpressure
from urine and peristaltic forces.[32] This necessitated a change in design of the stent to
include a radial expansion anchor method and a sheath for implantation. However, due to
the sheath design, the ASTM F 1828-97 anchor strength test was not applicable as there
was not a curl to pull against. Thus, a novel test methodology was implemented.
It was desired to update the anchor strength test to better simulate this physiologic
condition by applying a “push” similar to peristaltic forces instead of the “pull” of the
standard test. This was accomplished by threading a wire through the stent and fastening
it to the bottom of the stent, so that the top grip of the MTS machine can apply force to
the bottom of the implanted ureter. In this test, explanted porcine ureters were used to
provide a surface for the stent to anchor to. The force vs deflection curve (Figure 4-14)
exhibited an initial elastic region of the graph which is attributed to the ureter itself
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elongating and resisting the applied force. After roughly 1 cm of extension, a sharp
decrease in detected force is observed, this is believed to be the point at which the stent
moves within the ureter. There then follows a region of, low uneven force which
corresponds with the individual rings of the stent slipping from the ureter. The anchor
strength of a stent in a porcine ureter using this was on average 1.09±0.26N for a 3.9 cm
segment, which may be extrapolated to 7.82 N for a standard 28 cm full-length stent.
This is substantially higher compared to the strongest reported anchor strength values of
0.73 N and 0.62 N for the 6 french Cook Black Silicone and the Cook C- Flex stents
respectively. [87] Thus, it is believed that the proposed stent design will have adequate
anchor strength to operate in a clinical setting.

5.3 Characterization of Stent Degradation
To determine the rate of mass loss, an ex-vivo study was performed in a manner
similar to physiological conditions. Four stents were subjected to water at 37 °C at
typical ureteral flow rate and their mass was monitored weekly. After four weeks, data
could no longer be collected in the present study as the stent fractured and dissipated into
the flow apparatus. In this application, it is believed that this represents the time at which
the stent will break apart, flush into the bladder and then be expelled via urine. It should
be noted that this degradation time for the stent is much less than the typically reported
time of 6 months for PDO. [88], [89] This is because, in this application, the time of
strength loss of the PDO polymer equates to the time of stent fracture and migration into
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the bladder. It has been reported that PDO suture typically suffers a drop in tensile
strength of 65-90% after 4 weeks which aligns with our empirical data.
The mass of the stent was near consistent during the degradation study which
provides evidence that the PDO stent was undergoing bulk degradation. In general,
degrading polymers can erode in two ways. In surface erosion, the polymer degrades
from the surface while in bulk erosion, degradation occurs throughout the whole material
equally. As with nearly all polyesters, it has been shown that PDO undergoes bulk
degradation. [90] This is due to the water diffusing into the polymer and then cleaving
the ester bonds via hydrolysis. Hydrolytic degradation of ureteral stents in vivo would
occur via an acid catalyzed process as the urinary tract is typically under acidic
conditions (pH of 5.5-6.5 depending on diet). [84] This acid catalyzed degradation is
essentially the reverse of Fischer Esterification where an acidic molecule penetrates the
lamellar structure and cleaves the ester linkage. Degradation will depend on crystallinity
and morphology. [91]. In the present study, degradation experiments were conducted in
neutral deionized water (initial pH =7) with a regularly replaced reservoir used to dilute
the acidic dioxanone polymer degradation products in the system. The main concern
when conducting this study was if the stent would last too long, as in the majority of
clinical cases, the stent is removed within 4 weeks. By performing the test under near
neutral pH conditions, it is believed that the presented data represents an upper bound of
stent degradation time and thus a worst case for stent implantation time.
The solution viscosity of a polymer is intrinsically tied to the molecular weight of
a polymer. Essentially, the longer polymer chains are more prone to tangle in solution
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and thus resist the fluid flow. The results of the solution viscosity testing provided
evidence of a 12.7% decrease in viscosity after processing (Figure 4-10). Compared to
the unprocessed suture (1.58±0.07 dL/g), the viscosity of the processed stent was
1.38±0.07 dL/g. The decrease in viscosity indicates that there is degradation occurring in
the polymer during processing. The three primary methods of polymer degradation are
chemical, thermal, and ultraviolet. Based on the DSC results (Figure 4.3), and the
annealing process conditions, it is unlikely that the polymer experienced thermal or
ultraviolet degradation. The most plausible explanation is that ambient moisture in the
air provided enough initiator to start hydrolysis within the polymer. [92] Even though
some degradation occurred in the stent during the annealing process, this may aid the
final stent function as the stent will degrade in a shorter time which is more clinically
relevant.

5.4 Physical Characterization of Stent
The presence of an ether peak (1320-1000), an ester peak (1750-1735), and the
aldehyde group (2830-2695), indicated the expected structure of the PDO. The FTIR
results verified that the polymer utilized to manufacture the stent was only PDO and was
not contaminated by foreign substances during synthesis or sample preparation (Figure
4-7). The results of thermogravimetric analysis (TGA) revealed that both the processed
and unprocessed stent reached 0% mass at 350 °C indicating the maximum molecular
weight of both processed and unprocessed stents were the same. However, the graph also
showed that processed stent started decreasing in mass at a lower temperature (Figure
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4-2). This can be explained when molecular weight is viewed as a distribution of polymer
chains. The data suggest that the unprocessed PDO polymer chains are uniform in length
and, once temperature reached the sublimation temperature, they into the vapor phase
simultaneously. In contrast, the processed stent exhibited an earlier deflection of the
TGA curve at 200 °C compared to the unprocessed stent at 250 °C. This earlier sign of
mass loss indicates that presence of smaller molecules that are easier to vaporize and
removed from the polymer. This indicates degradation of the longer polymer chains into
shorter ones during processing.
The primary aim in DSC testing was to determine the percent crystallinity of the
polymers before and after processing. The enthalpy of fusion of a 100% crystalline
polymer has been reported to be equal to 14400 J/mol. [93] Given a molar mass of 102
g/mol for PDO, this yields an enthalpy of melting of 141.12 J/g. The experimentally
determined average enthalpy of fusion for the processed stent was 105.19 J/g while the
unprocessed stent was measured to be 92.68 J/g. Dividing these values by the enthalpy
of melting of 100% crystalline PDO yields a 74.50% crystallinity for processed stent
samples and a 65.64% crystallinity for unprocessed suture. This gives an 8.86% increase
in crystallinity due to processing.
This increase in crystallinity was further confirmed by the results of wide angle x-ray
scattering (Figure 4-9). The intensity of the x-ray scatter showed a bimodal curve with an
8.9% increase in intensity in processed stents. Additionally, there is a slight shift of 0.26
degree in both the peaks toward a larger angle after processing the PDO suture into the
stent. (Figure 4-9)
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From the Bragg equation, ( 2𝑑𝑠𝑖𝑛𝜃 = 𝜆) given a 0.154 nm radiation wavelength, the
lattice spacing of the suture was calculated to be 0.209 nm and 0.194 nm while the
spacing for the stent was 0.207 nm and 0.192 nm. This decrease in lattice spacing is
attributed to degradation of the polymer which was confirmed by IV testing. The cleaved
polymer chains of the stent are shorter than the undegraded polymer chains of the suture.
This allows the polymers to rest more closely to each other and slightly decreases the
spacing between polymer chains.
The results of the DSC and WAXS data indicate there is an 8.9% increase in
crystallinity during processing. PDO polymer typically exhibits a higher crystallinity
than other degradable polymers such as PLA, one of the main reasons being lack of steric
hindrance. This is also why PDO has a very low glass transition temperature of around 10 °C. [94] It can be speculated that this 8.9% increase in crystallinity is due to the
added energy placed in the polymer from the 24 hours heat at 100 °C. This thermal
energy allowed the amorphous polymer chains to move until they were in a more
thermodynamically favorable position when the polymer is more crystalline. It is
believed this crystallinity increase is the reason the annealed PDO is stiffer than the
unannealed PDO. Thus, it is has been demonstrated that flexible, amorphous PDO can
be formed into a spiral shape and “locked” into shape by annealing the material to
increase its crystallinity.
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6. CONCLUSION
In the present study, a biodegradable stent was designed and fabricated to solve
many of the issues with current ureteral stents. These include, encrustation, urgency,
pain, and most importantly the need for a follow up removal surgery. The proposed
design features the use of biodegradable, FDA approved polydioxanone polymer material
that was aimed to reduce encrustation and eliminate the need for a removal surgery.
Additionally, the stent uses a coiled shape to anchor into the ureter, which will prevent
the issue of the proximal anchor pressing on the bladder, remove the risk of encrustation
on the distal anchor, and provide for better patient comfort by creating a more axially
flexible stent. The results of the present study provided evidence that the stent exhibits
adequate radial strength to maintain patency and can meet ureteral flow rate
requirements. It was concluded that annealing PDO suture led to an increase in the
polymer crystallinity and stiffness of the material. Moreover, an in vitro experiment
demonstrated that the stent degrades in four weeks under physiological conditions, which
is believed to be the ideal degradation time for the majority of ureteral stent applications.
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7. FUTURE WORK

Future work should address the gaps in the stent characterization to ensure patient
safety after implantation.
1. To determine the stent degradation profile, animal trials should be conducted to
verify safety.

Rationale: While stent degradation was studied in near physiological conditions
in vitro, the degradation profile was not explored in vivo.

Approach: A porcine animal model is typically used for a urinary system the stent
should be monitored over the course of implantation using ultrasound or
fluoroscopic techniques to track the stent degradation. Following implantation
excretory urogram and blood tests would verify that adequate urine flow is
occurring. After 5 weeks, all pigs should undergo necroscopy and undergo
histological evaluation to verify no damage was done to the urinary tract during
degradation.

2. A full sized stent and full sized sheath should be manufactured to verify efficacy
of the implantation procedure.
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Rationale: While implantation was proven feasible with approximately 4 cm stent
segments, implantation was not attempted with a full sized stent.

Approach: Replacement of the tested silicone sheath with a material with a lower
coefficient of friction will likely aid in implantation. One potential sheath
material is Polytetrafluoroethylene (PTFE). This full sized stent should be
implanted during the proposed animal study using standard urological techniques
to verify implantation method.

3. An encrustation experiment using artificial urine should be conducted.

Rationale: it has been hypothesized that one of the benefits of utilizing a
biodegradable stent is that it will reduce stent encrustation when compared to
current stents on the market.

Approach: Encrustation could be quantified by measuring mass gain over time of
a stent submersed in solution. Ideally, the typical stent materials of silicone and
polyurethane would be tested under the same experimental conditions to compare
the biodegradable material with current standards.
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APPENDIX
Code for Pressure Vessel Used in Radial Strength Testing

#include <Wire.h>
#include <Adafruit_BMP085.h>
// Connect VCC of the BMP085 sensor to 3.3V (NOT 5.0V!)
// Connect GND to Ground
// Connect SCL to i2c clock - on '168/'328 Arduino Uno/Duemilanove/etc thats Analog 5
// Connect SDA to i2c data - on '168/'328 Arduino Uno/Duemilanove/etc thats Analog 4
// EOC is not used, it signifies an end of conversion
// XCLR is a reset pin, also not used here
Adafruit_BMP085 bmp;
void setup() {
Serial.begin(115200);
if (!bmp.begin()) {
Serial.println("Could not find a valid BMP085 sensor, check wiring!");
while (1) {}
}
}
void loop() {
//Serial.print("Pressure = ");
Serial.print(bmp.readPressure());
//Serial.println(" Pa");
Serial.println();
delay(100); //sampling every 100ms
}
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